CRL logo

CRL

Profile

Full Name

Charles River Laboratories International, Inc.

Ticker Symbol

CRL

Exchange

NYSE

Sector

Healthcare

Industry

Diagnostics & Research

Country

United States

IPO

June 23, 2000

Indexes

S&P 500

Website

http://www.criver.com

Employees

18700

Key Details

Price

$114.66(-0.95%)

Market cap

$5.86B(Mid cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$4.05B(-1.92% YoY)

Annual EPS

$0.20(-97.83% YoY)

PE ratio

764.40

Next earnings date

May 7, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$114.66
CRL price is $114.66

30-Day Relative Volume

0.74
CRL 30-day relative volume is 0.74

Price Performance

Price Most recent change

-0.95%
CRL price was down -0.95% on Apr 25, 2025

Price YTD change

-37.89%
CRL price is down -37.89% since January 1st

Price 1-year change

-49.67%
CRL price is down -49.67% year-on-year

Price 3-year change

-54.74%
CRL price is down -54.74% over the past 3 years

Price Range

Price All-time high

$460.21
CRL price is currently -75.09% below its historical high of $460.21

Price 3-year low

$91.86
CRL price is currently +24.82% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$5.86B
CRL market capitalization is $5.86 billion

Market cap 3-year change

-54.44%
CRL market capitalization is down -54.44% over the past 3 years

Market cap All-time high

$23.13B
CRL market capitalization is currently -74.64% below its historical high of $23.13 billion

Market cap sector rank

89.73%
CRL market capitalization is higher than 89.73% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

-0.72%
CRL shares outstanding is down -0.72% year-on-year

Shares Outstanding 3-Year Change

+0.66%
CRL shares outstanding is up +0.66% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.34
CRL beta is 1.34

200-day SMA

$183.10
CRL price is currently -37.38% below its 200-day simple moving average

50-day SMA

$148.54
CRL price is currently -22.81% below its 50-day simple moving average

RSI

39.89
CRL 14-day relative strength index is 39.89

Volume

0.74
CRL 30-day relative volume is 0.74

ATR

$7.19
CRL average true range is $7.19

10-day Historical Volatility

53.68%
CRL 10-day historical volatility is 53.68%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$4.05B
CRL annual revenue is $4.05 billion

Revenue Analysts estimate

$3.82B
CRL annual revenue is currently +5.94% higher than the consensus analysts' forecast

Revenue 1-year change

-1.92%
CRL annual revenue is down -1.92% year-on-year

Revenue Sector rank

90.67%
CRL annual revenue is higher than 90.67% of companies in Healthcare sector

EPS

EPS

$0.20
CRL annual earnings per share is $0.20

EPS Analysts estimate

$9.31
CRL annual earnings per share is currently -97.85% lower than the consensus analysts' forecast

EPS 1-year change

-97.83%
CRL annual earnings per share is down -97.83% year-on-year

EPS Sector rank

84.89%
CRL annual earnings per share is higher than 84.89% of companies in Healthcare sector

Profit

Gross profit

$1.33B
CRL annual gross profit is $1.33 billion

Gross margin

32.88%
CRL annual gross profit margin is 32.88%

Operating profit

$442.35M
CRL annual operating income is $442.35 million

Operating margin

10.92%
CRL annual operating profit margin is 10.92%

Net income

$22.20M
CRL annual net profit is $22.20 million

Net margin

0.55%
CRL annual net profit margin is 0.55%

Expenses

Total expenses

$3.61B
CRL annual total expenses is $3.61 billion

Operating expenses

$889.47M
CRL annual total operating expenses is $889.47 million

Cost of goods sold

$2.72B
CRL annual cost of goods sold is $2.72 billion

Selling, general & administrative expenses

$751.00M
CRL annual SGA is $751.00 million

Depreciation and amortization

$361.74M
CRL annual depreciation & amortization is $361.74 million

Interest expense

$126.29M
CRL annual interest expense is $126.29 million

Income tax

$67.82M
CRL annual income tax is $67.82 million

EBIT & EBITDA

EBIT

$219.40M
CRL annual earnings before interest & taxes is $219.40 million

EBITDA

$581.14M
CRL annual EBITDA is $581.14 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$7.53B
CRL annual total assets is $7.53 billion

Non current assets

$6.13B
CRL annual long term assets is $6.13 billion

Current assets

$1.40B
CRL annual total current assets is $1.40 billion

Cash and cash equivalents

$194.61M
CRL annual cash & cash equivalents is $194.61 million

Accounts receivable

$527.71M
CRL annual accounts receivable is $527.71 million

Inventory

$278.54M
CRL annual inventory is $278.54 million

Liabilities

Total liabilities

$4.02B
CRL annual total liabilities is $4.02 billion

Long term liabilities

$3.03B
CRL annual total long term liabilities is $3.03 billion

Current liabilities

$994.10M
CRL annual total current liabilities is $994.10 million

Accounts payable

$140.34M
CRL annual accounts payable is $140.34 million

Debt

Total debt

$2.72B
CRL annual total debt is $2.72 billion

Total debt 1-year change

-11.17%
CRL annual total debt is down -11.17% year-on-year

Long term debt

$2.72B
CRL annual long term debt is $2.72 billion

Short term debt

-
CRL annual short term debt value is unknown

Equity & Capital

Shareholders equity

$3.46B
CRL annual stockholders equity is $3.46 billion

Book value

$3.46B
CRL annual book value is $3.46 billion

Retained earnings

$1.81B
CRL annual retained earnings is $1.81 billion

Working capital

$408.97M
CRL annual working capital is $408.97 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

$734.58M
CRL annual cash flow from operations is $734.58 million

Cash from operations 1-year change

+7.41%
CRL annual cash flow from operations is up +7.41% year-on-year

Cash from investing

-$245.09M
CRL annual cash flow from investing activities is -$245.09 million

Cash from investing 1-year change

+56.48%
CRL annual cash flow from investing activities is up +56.48% year-on-year

Cash from financing

-$550.93M
CRL annual cash flow from financing activities is -$550.93 million

Cash from financing 1-year change

-544.2%
CRL annual cash flow from financing activities is down -544.2% year-on-year

CAPEX

CAPEX

$232.97M
CRL annual capital expenditures is $232.97 million

CAPEX 1-year change

-26.86%
CRL annual capital expenditures is down -26.86% year-on-year

Free Cash Flow

Free cash flow

$501.61M
CRL annual free cash flow is $501.61 million

Free cash flow 1-year change

+37.29%
CRL annual free cash flow is up +37.29% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

32.88%
CRL annual gross profit margin is 32.88%

Operating margin

10.92%
CRL annual operating profit margin is 10.92%

Net margin

0.55%
CRL annual net profit margin is 0.55%

ROA & ROE

ROA

0.28%
CRL annual return on assets is 0.28%

ROE

0.62%
CRL annual return on equity is 0.62%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

764.40
CRL price to earnings ratio is 764.40

PE ratio Sector rank

99.51%
CRL price to earnings ratio is higher than 99.51% of companies in Healthcare sector

PB Ratio

PB ratio

1.69
CRL price to book ratio is 1.69

PB ratio Sector rank

56.48%
CRL price to book ratio is higher than 56.48% of companies in Healthcare sector

PS Ratio

PS ratio

1.45
CRL price to sales ratio is 1.45

PS ratio Sector rank

33.9%
CRL price to sales ratio is higher than 33.9% of companies in Healthcare sector

Enterprise value

Enterprise value

$8.39B
CRL enterprise value is $8.39 billion

Enterprise value Sector rank

91.24%
CRL enterprise value is higher than 91.24% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

14.44
CRL EV/EBITDA is 14.44

EV/EBITDA Sector rank

87.42%
CRL EV/EBITDA is higher than 87.42% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

1.41
CRL annual current ratio is 1.41

Quick ratio

1.13
CRL annual quick ratio is 1.13

Leverage

Debt to equity

0.65
CRL annual debt to equity ratio is 0.65

Interest coverage ratio

1.74
CRL annual interest coverage ratio is 1.74

Risk & Stability

Piotroski F-Score

6
CRL piotroski f-score is 6

Altman Z-Score

1.91
CRL altman z-score is 1.91

Analyst ratings

Recent major analysts updates

Apr 10, 25 Barclays
Equal-Weight
Apr 9, 25 Mizuho
Neutral
Mar 21, 25 Goldman Sachs
Neutral
Mar 4, 25 Citigroup
Neutral
Feb 20, 25 JP Morgan
Neutral
Feb 20, 25 Barclays
Equal-Weight
Feb 20, 25 Baird
Neutral
Feb 18, 25 Barclays
Equal-Weight
Feb 5, 25 Morgan Stanley
Equal-Weight
Feb 3, 25 JP Morgan
Neutral

Institutional Ownership

Similar stocks

SRPT logo
Sarepta Therapeutics (SRPT)
STVN logo
Stevanato Group SpA (STVN)
BRKR logo
Bruker (BRKR)
GH logo
Guardant Health (GH)
BPMC logo
Blueprint Medicines (BPMC)
MMSI logo
Merit Medical Systems (MMSI)
VRNA logo
Verona Pharma (VRNA)
GKOS logo
Glaukos (GKOS)
TFX logo
Teleflex Incorporated (TFX)
  • What is the ticker symbol for Charles River Laboratories International?
  • Does Charles River Laboratories International pay dividends?
  • What sector is Charles River Laboratories International in?
  • What industry is Charles River Laboratories International in?
  • What country is Charles River Laboratories International based in?
  • When did Charles River Laboratories International go public?
  • Is Charles River Laboratories International in the S&P 500?
  • Is Charles River Laboratories International in the NASDAQ 100?
  • Is Charles River Laboratories International in the Dow Jones?
  • When was Charles River Laboratories International's last earnings report?
  • When does Charles River Laboratories International report earnings?
  • Should I buy Charles River Laboratories International stock now?

What is the ticker symbol for Charles River Laboratories International?

The ticker symbol for Charles River Laboratories International is NYSE:CRL

Does Charles River Laboratories International pay dividends?

No, Charles River Laboratories International does not pay dividends

What sector is Charles River Laboratories International in?

Charles River Laboratories International is in the Healthcare sector

What industry is Charles River Laboratories International in?

Charles River Laboratories International is in the Diagnostics & Research industry

What country is Charles River Laboratories International based in?

Charles River Laboratories International is headquartered in United States

When did Charles River Laboratories International go public?

Charles River Laboratories International's initial public offering (IPO) was on June 23, 2000

Is Charles River Laboratories International in the S&P 500?

Yes, Charles River Laboratories International is included in the S&P 500 index

Is Charles River Laboratories International in the NASDAQ 100?

No, Charles River Laboratories International is not included in the NASDAQ 100 index

Is Charles River Laboratories International in the Dow Jones?

No, Charles River Laboratories International is not included in the Dow Jones index

When was Charles River Laboratories International's last earnings report?

Charles River Laboratories International's most recent earnings report was on Feb 19, 2025

When does Charles River Laboratories International report earnings?

The next expected earnings date for Charles River Laboratories International is May 7, 2025

Should I buy Charles River Laboratories International stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page